Sudeh Izadmehr

8PUBLICATIONS
87CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyInnate immunityPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 19, 2026
Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial.

|Feb 26, 2026
A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.

Michelle A Tran, Byuri Angela Cho, Sudeh Izadmehr

|Jan 24, 2025
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer.

Matthew D Galsky, Mark Kockx, Juliette Roels

|Feb 14, 2024
Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis.

Sudeh Izadmehr, Heriberto Fernandez-Hernandez, Danica Wiredja

|Jan 19, 2024
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.

Matthew D Galsky, Siamak Daneshmand, Sudeh Izadmehr

|Oct 02, 2023
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.

Matthew D Galsky, Siamak Daneshmand, Sudeh Izadmehr

Pageof 2

Frequent Collaborators

6 joint publications

Sacha Gnjatic

6 joint publications

Matthew D Galsky

4 joint publications

Edgar Gonzalez-Kozlova

3 joint publications

Nina Bhardwaj